Table 1. Summary of important recommendations.
No. | Recommendation | GoR | Consensus (source) |
Symptoms and risk factors | |||
2–1 | The patient should have regular ophthalmological examinations, because:
|
↑↑ | expert consensus |
2–2 | The following are warning signs of retinal complications:
|
statement | expert consensus |
2–3 | Important general risk factors for the appearance or progression of diabetic retinopathy and/or maculopathy are:
|
statement | expert consensus (9– 15) |
Clinical examination and general treatment strategies | |||
3–2 | On referral to the ophthalmologist, the patient should be told not to drive a motor vehicle for a few hours after the ophthalmological examination because the pupils must be dilated as part of the procedure. | ↑↑ | expert consensus |
3–3 | The ophthalmological examination for the detection of retinopathy and/or maculopathy and the determination of its severity should include the following:
|
↑↑ | expert consensus |
3–4 | The intraocular pressure should be measured in patients with advanced retinopathy. In certain clinical situations, fluorescein angiography is indicated. |
↑↑ | expert consensus (16, 17) |
Interval between ophthalmological examinations | |||
4–1 | The regular ophthalmological examination of diabetics enables the early diagnosis of pathological changes so that the patient‘s treatment can be adjusted as needed and any indicated ophthalmological treatments can be provided. | statement | expert consensus |
4–2 | Ophthalmological screening should be performed
|
↑↑ | |
4–6 | Patients should be seen promptly by an ophthalmologist if they develop any of the following new symptoms:
|
↑↑ | expert consensus |
Treatment by the primary care physician/diabetologist | |||
5–2 | The patient should be told that the presence of retinopathy is not a contraindication for cardioprotective ASA treatment, as the latter does not elevate the risk of retinal hemorrhage. | ↑ | expert consensus (18– 20) |
5–7 | If both focal and panretinal laser coagulation are indicated in a patient with combined proliferative diabetic retinopathy and diabetic macular edema without foveal involvement, the maculopathy should be treated first. | ↑ | expert consensus |
Severe complications of proliferative diabetic retinopathy | |||
5–8 | Vitrectomy should be offered to patients who have a non-resorbing vitreal hemorrhage or a present or impending central traction retinal detachment. | ↑↑ | expert consensus (21– 23) |
Treatment of clinically significant diabetic macular edema | |||
…without foveal involvement | |||
5–9 | Focal laser coagulation can be offered to patients with clinically significant diabetic macular edema that spares the fovea but threatens to impair visual acuity. | ↔ | (24– 27) |
… with foveal involvement | |||
5–11 | Intravitreal steroid therapy can be offered to patients with an inadequate or absent response to intravitreal therapy with VEGF inhibitors. | ↔ | expert consensus (28) |
Provision of magnifying visual aids | |||
5–14 | Patients who lose the ability to read despite best refractive correction and whose blood glucose levels and ophthalmological findings are stable should be offered magnifying visual aids (either optical or electronic). | ↑ | expert consensus |
Recommendations are numbered as in the guideline. ↑↑ strong recommendation, ↑ weak recommendation, ↔ open recommendation.
ASA, acetylsalicylic acid; GoR, grade of recommendation; PDR, proliferative diabetic retinopathy; VEGF, vascular endothelial growth factor